FAS and neoplasm: Aside from the pro-apoptotic effect on tumor cells, bortezomib can sensitize tumor cells to NK cells by decreasing expression of peptide–MHC class I complexes [130] and increasing tumor cell surface expression of FAS and the TNF-related apoptosis-inducing ligand (TRAIL) receptor DR5 [131].